Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice

Abstract

The outcome of chronic myeloid leukemia (CML) patients improved in the last decade. Clinical prognostic scoring systems aim to provide information about survival in the long-term, without determining from baseline the subset of patients who require a strictly monitoring because at increased risk of failure. Imatinib, the first-generation tyrosine kinase inhibitor (TKI), is still widely used as frontline treatment: recently, the imatinib therapy failure (IMTF) score was proposed to identify the failure free survival. Aim of our study was to validate this index in a large cohort of patients treated with imatinib.

Keywords:

• chronic myeloid leukemia
• imatinib
• failure
• prognosis

Authors’ contributions

CI, MB wrote the paper; ES, IC, MLB followed the patients; SP performed statistical analysis; MM approved the final version of the paper.

Disclosure statement

MB received honoraria by Novartis, BMS/Celgene, Pfizer, Incyte. All the other authors have no conflict of interests.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.